Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025

Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 studyPresentation of digital ...
University of Denver

Faculty and Staff Grants From Summer 2025

May Faculty and Staff GrantsRestrictedCasey Myers, Ritchie School of Engineering & Computer ScienceFunder: RestrictedAbstract ...

Roadzen’s DrivebuddyAI Secures EU’s General Safety Regulation 2144 Compliance, Becomes the World’s Only Driver Monitoring System Validated Under Both Indian and EU Safety ...

DrivebuddyAI crosses 3.5 billion kilometers of real-world driving data with 70%+ accident reduction, underscoring Roadzen’s global leadership in ...
The Malaysian Reserve

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- ...

SOLIGENIX, INC.: Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: ...
Cantech Letter

Graphano Reports 8.61 Metres Grading 11.33% Cg from Drilling Program at the Black Pearl Graphite Project

Graphano Energy Ltd. (TSXV: GEL) (OTC Pink: GELEF) (FSE: 97G0) (“Graphano” or the “Company”) is pleased to report initial assay ...

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct ...

Detailed price information for Biomea Fusion Inc (BMEA-Q) from The Globe and Mail including charting and trades.
Santé log

Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find ...

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication ...

Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support (PS) (comprised of total parenteral nutrition ...
PharmiWeb

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once ...

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose ...

Graphano Energy Ltd.: Graphano Reports 8.61 Metres Grading 11.33% Cg from Drilling Program at the Black Pearl Graphite Project

Graphano Energy Ltd. (TSXV: GEL) (OTC Pink: GELEF) (FSE: 97G0) ("Graphano" or the "Company") is pleased to report initial assay results ...

Digital Therapeutics Market Size to Lead USD 56.76 Bn by 2034 Driven by Digital Therapeutics, Cost Control, and Chronic Disease Prevalence

The global digital therapeutics market size is predicted to increase from USD 9.73 billion in 2025 and is anticipated to be worth around USD 56.76 billion by 2034, expanding at a CAGR of 21.83% from ...